Business Description
Nykode Therapeutics AS
ISIN : NO0010714785
Share Class Description:
VACBF: Ordinary SharesCompare
Compare
Traded in other countries / regions
NYKD.NorwayVACBF.USANYKDo.Sweden5VB.GermanyNYKDo.UK IPO Date
2020-10-09Description
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 28.71 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 8.42 | |||||
| Beneish M-Score | 175.05 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -58.5 | |||||
| 3-Year Book Growth Rate | 0.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 16.24 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 98.45 | |||||
| 9-Day RSI | 88.7 | |||||
| 14-Day RSI | 76.72 | |||||
| 6-1 Month Momentum % | -20.89 | |||||
| 12-1 Month Momentum % | -45.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.43 | |||||
| Quick Ratio | 8.43 | |||||
| Cash Ratio | 8.17 | |||||
| Days Sales Outstanding | 6.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.7 | |||||
| Shareholder Yield % | -0.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -553.47 | |||||
| Net Margin % | -373.34 | |||||
| FCF Margin % | -865.69 | |||||
| ROE % | -26.65 | |||||
| ROA % | -20.58 | |||||
| ROIC % | -116.74 | |||||
| ROC (Joel Greenblatt) % | -466.7 | |||||
| ROCE % | -28.89 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 41.11 | |||||
| PB Ratio | 2.88 | |||||
| Price-to-Tangible-Book | 2.88 | |||||
| EV-to-EBIT | -6.39 | |||||
| EV-to-EBITDA | -6.69 | |||||
| EV-to-Forward-EBITDA | -4.88 | |||||
| EV-to-Revenue | 29.29 | |||||
| EV-to-Forward-Revenue | 15.2 | |||||
| EV-to-FCF | -3.41 | |||||
| Price-to-Net-Current-Asset-Value | 3.85 | |||||
| Price-to-Net-Cash | 3.95 | |||||
| Earnings Yield (Greenblatt) % | -15.65 | |||||
| FCF Yield % | -20.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:VACBF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nykode Therapeutics AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.603 | ||
| EPS (TTM) ($) | -0.13 | ||
| Beta | 0 | ||
| Volatility % | 37.98 | ||
| 14-Day RSI | 76.72 | ||
| 14-Day ATR ($) | 0.007572 | ||
| 20-Day SMA ($) | 1.452 | ||
| 12-1 Month Momentum % | -45.41 | ||
| 52-Week Range ($) | 1.25 - 2.36 | ||
| Shares Outstanding (Mil) | 326.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nykode Therapeutics AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nykode Therapeutics AS Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nykode Therapeutics AS Frequently Asked Questions
What is Nykode Therapeutics AS(VACBF)'s stock price today?
The current price of VACBF is $1.50. The 52 week high of VACBF is $2.36 and 52 week low is $1.25.
When is next earnings date of Nykode Therapeutics AS(VACBF)?
The next earnings date of Nykode Therapeutics AS(VACBF) is 2024-08-21.
Does Nykode Therapeutics AS(VACBF) pay dividends? If so, how much?
Nykode Therapeutics AS(VACBF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers